A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the GlaxoSmithKline (GSK) Biologicals' Respiratory Syncytial Virus (RSV) Investigational Vaccine (GSK3003891A) in Healthy Pregnant Women and Infants Born to Vaccinated Mothers

Condition:   Respiratory Syncytial Virus Infections Interventions:   Biological: RSV vaccine (GSK3003891A) formulation 1;   Biological: RSV vaccine (GSK3003891A) formulation 2;   Biological: RSV vaccine (GSK3003891A) formulation 3;   Drug: Placebo (Formulation buffer S9b) Sponsor:   GlaxoSmithKline Not yet recruiting - verified June 2017
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials